Company news
Cellectis S.a. (EURONEXT:ALCLS) news
Every Cellectis S.a. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Cellectis to Report Second Quarter Financial Results on August 6, 2026
July 30, 2026
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
June 25, 2026
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
June 11, 2026
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
June 9, 2026
Cellectis S A : Report of the Board of Directors - Combined General Meeting of Shareholders - June 25, 2026
May 29, 2026
Cellectis S A : Notice of Meeting - Combined General Meeting of Shareholders - June 25, 2026
May 20, 2026
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
May 12, 2026
Cellectis Reports Financial Results for the First Quarter 2026
May 11, 2026
Cellectis to Report First Quarter Financial Results on May 11, 2026
May 4, 2026
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
April 27, 2026
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
April 13, 2026
Monthly information on share capital and company voting rights
April 7, 2026
Cellectis S A : Annual Report for Fiscal Year Ending December 31, 2025 (Form 20-F)
March 20, 2026
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
March 19, 2026
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
March 12, 2026
Cellectis Announces 2026 Strategy and Catalysts
January 8, 2026
Cellectis Announces Arbitral Decision in Dispute with Servier
December 15, 2025
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
December 8, 2025
Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications
November 21, 2025
Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic ...
November 19, 2025
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
November 7, 2025
Cellectis to Present a Development Update for eti-cel at ASH 2025
November 3, 2025
Cellectis to Report Third Quarter Financial Results on November 7, 2025
October 31, 2025
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
October 16, 2025
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
October 16, 2025
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
October 7, 2025
Factor Bioscience Files Complaint Against Cellectis and AstraZeneca Alleging Infringement of Foundational Gene-Editing Patents
September 26, 2025
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
August 4, 2025
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
July 28, 2025
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
June 26, 2025
Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025
May 21, 2025
Cellectis Reports Financial Results for the First Quarter 2025
May 12, 2025
Cellectis to Report First Quarter Financial Results on May 12, 2025
May 6, 2025
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
April 28, 2025